0(0%) Volume: 551,756 1:15AM EST| Market Cap : 3.27 B | Enterprise Value : 2.6 B | P/E (TTM) : | P/B : 4.29 |
|---|
NAS:AGIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:AGIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | No Debt |
NAS:AGIO's Cash-to-Debt is ranked higher than
77% of the 1078 Companies in the Global Biotechnology industry. ( Industry Median: 64.02 vs. NAS:AGIO: No Debt ) Ranked among companies with meaningful Cash-to-Debt only. |
NAS:AGIO'
s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt Current: No Debt |
| Equity-to-Asset | 0.82 |
NAS:AGIO's Equity-to-Asset is ranked higher than
72% of the 763 Companies in the Global Biotechnology industry. ( Industry Median: 0.69 vs. NAS:AGIO: 0.82 ) Ranked among companies with meaningful Equity-to-Asset only. |
NAS:AGIO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26 Med: 0.67 Max: 0.9 Current: 0.82 |
| Interest Coverage | No Debt |
NAS:AGIO's Interest Coverage is ranked higher than
72% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. NAS:AGIO: No Debt ) Ranked among companies with meaningful Interest Coverage only. |
NAS:AGIO'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt Current: No Debt |
| Piotroski F-Score: 4 |
|
| Altman Z-Score: 9.42 |
|
| Beneish M-Score: -1.81 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -480.30 |
NAS:AGIO's Operating Margin % is ranked lower than
68% of the 792 Companies in the Global Biotechnology industry. ( Industry Median: -113.97 vs. NAS:AGIO: -480.30 ) Ranked among companies with meaningful Operating Margin % only. |
NAS:AGIO'
s Operating Margin % Range Over the Past 10 Years
Min: -745.84 Med: -152.2 Max: -76.16 Current: -480.3 |
| Net Margin % | -461.78 |
NAS:AGIO's Net Margin % is ranked lower than
68% of the 792 Companies in the Global Biotechnology industry. ( Industry Median: -111.91 vs. NAS:AGIO: -461.78 ) Ranked among companies with meaningful Net Margin % only. |
NAS:AGIO'
s Net Margin % Range Over the Past 10 Years
Min: -731.6 Med: -154.25 Max: -80.07 Current: -461.78 |
| ROE % | -52.30 |
NAS:AGIO's ROE % is ranked lower than
56% of the 989 Companies in the Global Biotechnology industry. ( Industry Median: -42.82 vs. NAS:AGIO: -52.30 ) Ranked among companies with meaningful ROE % only. |
NAS:AGIO'
s ROE % Range Over the Past 10 Years
Min: -85.73 Med: -49.69 Max: -19.25 Current: -52.3 |
| ROA % | -40.12 |
NAS:AGIO's ROA % is ranked lower than
54% of the 1084 Companies in the Global Biotechnology industry. ( Industry Median: -34.77 vs. NAS:AGIO: -40.12 ) Ranked among companies with meaningful ROA % only. |
NAS:AGIO'
s ROA % Range Over the Past 10 Years
Min: -51.02 Med: -23.3 Max: -12.13 Current: -40.12 |
| ROC (Joel Greenblatt) % | -1472.98 |
NAS:AGIO's ROC (Joel Greenblatt) % is ranked lower than
63% of the 1036 Companies in the Global Biotechnology industry. ( Industry Median: -521.46 vs. NAS:AGIO: -1472.98 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
NAS:AGIO'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1472.98 Med: -827.83 Max: -516.17 Current: -1472.98 |
| 3-Year Revenue Growth Rate | -21.90 |
NAS:AGIO's 3-Year Revenue Growth Rate is ranked lower than
70% of the 651 Companies in the Global Biotechnology industry. ( Industry Median: 1.10 vs. NAS:AGIO: -21.90 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
NAS:AGIO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.9 Med: 8.1 Max: 27.6 Current: -21.9 |
| 3-Year EBITDA Growth Rate | -62.70 |
NAS:AGIO's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 802 Companies in the Global Biotechnology industry. ( Industry Median: 4.60 vs. NAS:AGIO: -62.70 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
NAS:AGIO'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.7 Med: -40.6 Max: -27.1 Current: -62.7 |
| 3-Year EPS without NRI Growth Rate | -61.90 |
NAS:AGIO's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 763 Companies in the Global Biotechnology industry. ( Industry Median: 5.70 vs. NAS:AGIO: -61.90 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
NAS:AGIO'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: -50.3 Max: -21.5 Current: -61.9 |
| Jim Simons 69,100 sh (New) Leon Cooperman 45,000 sh (New) Eaton Vance Worldwide Health Sciences Fund 43,741 sh (New) Vanguard Health Care Fund 4,353,124 sh (+12.34%) Steven Cohen 406,090 sh (+343.81%) |
| Leon Cooperman Sold Out Jim Simons Sold Out Vanguard Health Care Fund 4,233,424 sh (-2.75%) Steven Cohen 155,200 sh (-61.78%) Eaton Vance Worldwide Health Sciences Fund 31,276 sh (-28.50%) |
| Pioneer Investments 9,400 sh (New) Steven Cohen 175,700 sh (+13.21%) | Eaton Vance Worldwide Health Sciences Fund 31,276 sh (unchged) Vanguard Health Care Fund 4,233,424 sh (unchged) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | OSTO:SOBI, NAS:UTHR, SZSE:000661, NAS:AVXS, NAS:SRPT, NAS:BPMC, XKRX:128940, SZSE:002007, BOM:532523, HKSE:01548, XBRU:ABLX, HKSE:01530, SHSE:600201, NAS:TECH, NAS:FGEN, SZSE:300347, NAS:AAAP, LSE:BTG, LSE:ABC, TSE:4587 » details | |
| Traded in other countries: | 8AP.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 4.29 |
AGIO's PB Ratio is ranked lower than
59% of the 962 Companies in the Global Biotechnology industry. ( Industry Median: 4.10 vs. AGIO: 4.29 ) Ranked among companies with meaningful PB Ratio only. |
AGIO'
s PB Ratio Range Over the Past 10 Years
Min: 3.27 Med: 6.56 Max: 16.81 Current: 4.29 |
| PS Ratio | 42.57 |
AGIO's PS Ratio is ranked lower than
77% of the 726 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. AGIO: 42.57 ) Ranked among companies with meaningful PS Ratio only. |
AGIO'
s PS Ratio Range Over the Past 10 Years
Min: 17.19 Med: 41.64 Max: 107.02 Current: 42.57 |
| EV-to-EBIT | -7.28 |
AGIO's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies in the Global Biotechnology industry. ( Industry Median: 22.17 vs. AGIO: -7.28 ) Ranked among companies with meaningful EV-to-EBIT only. |
AGIO'
s EV-to-EBIT Range Over the Past 10 Years
Min: -89.2 Med: -11.15 Max: -4.5 Current: -7.28 |
| EV-to-EBITDA | -7.41 |
AGIO's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies in the Global Biotechnology industry. ( Industry Median: 18.08 vs. AGIO: -7.41 ) Ranked among companies with meaningful EV-to-EBITDA only. |
AGIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -91.9 Med: -11.5 Max: -4.6 Current: -7.41 |
| EV-to-Revenue | 35.00 |
AGIO's EV-to-Revenue is ranked lower than
72% of the 771 Companies in the Global Biotechnology industry. ( Industry Median: 13.69 vs. AGIO: 35.00 ) Ranked among companies with meaningful EV-to-Revenue only. |
AGIO'
s EV-to-Revenue Range Over the Past 10 Years
Min: 8.1 Med: 36.65 Max: 101.6 Current: 35 |
| Current Ratio | 8.21 |
AGIO's Current Ratio is ranked higher than
73% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.46 vs. AGIO: 8.21 ) Ranked among companies with meaningful Current Ratio only. |
AGIO'
s Current Ratio Range Over the Past 10 Years
Min: 2.77 Med: 6.33 Max: 10.75 Current: 8.21 |
| Quick Ratio | 8.20 |
AGIO's Quick Ratio is ranked higher than
74% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. AGIO: 8.20 ) Ranked among companies with meaningful Quick Ratio only. |
AGIO'
s Quick Ratio Range Over the Past 10 Years
Min: 2.77 Med: 6.33 Max: 10.75 Current: 8.2 |
| Days Inventory | 90.65 |
AGIO's Days Inventory is ranked lower than
99.99% of the 481 Companies in the Global Biotechnology industry. ( Industry Median: 125.55 vs. AGIO: 90.65 ) Ranked among companies with meaningful Days Inventory only. |
AGIO'
s Days Inventory Range Over the Past 10 Years
Min: 0 Med: 0 Max: 90.65 Current: 90.65 |
| Days Sales Outstanding | 40.99 |
AGIO's Days Sales Outstanding is ranked lower than
80% of the 668 Companies in the Global Biotechnology industry. ( Industry Median: 64.17 vs. AGIO: 40.99 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AGIO'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.8 Med: 31.14 Max: 50.78 Current: 40.99 |
| Days Payable | 8.00 |
AGIO's Days Payable is ranked lower than
99.99% of the 536 Companies in the Global Biotechnology industry. ( Industry Median: 63.91 vs. AGIO: 8.00 ) Ranked among companies with meaningful Days Payable only. |
AGIO'
s Days Payable Range Over the Past 10 Years
Min: 0 Med: 0 Max: 8 Current: 8 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.60 |
AGIO's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 857 Companies in the Global Biotechnology industry. ( Industry Median: -13.40 vs. AGIO: -9.60 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AGIO'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.2 Med: -13.6 Max: -9.6 Current: -9.6 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Net-Cash | 6.53 |
AGIO's Price-to-Net-Cash is ranked lower than
55% of the 613 Companies in the Global Biotechnology industry. ( Industry Median: 7.29 vs. AGIO: 6.53 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
AGIO'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.18 Med: 9.45 Max: 15.14 Current: 6.53 |
| Price-to-Net-Current-Asset-Value | 6.21 |
AGIO's Price-to-Net-Current-Asset-Value is ranked lower than
57% of the 745 Companies in the Global Biotechnology industry. ( Industry Median: 6.45 vs. AGIO: 6.21 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
AGIO'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.79 Med: 8.9 Max: 14.24 Current: 6.21 |
| Price-to-Tangible-Book | 4.30 |
AGIO's Price-to-Tangible-Book is ranked higher than
50% of the 894 Companies in the Global Biotechnology industry. ( Industry Median: 5.32 vs. AGIO: 4.30 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
AGIO'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.13 Med: 7.02 Max: 10.28 Current: 4.3 |
| Price-to-Median-PS-Value | 1.02 |
AGIO's Price-to-Median-PS-Value is ranked lower than
71% of the 678 Companies in the Global Biotechnology industry. ( Industry Median: 0.92 vs. AGIO: 1.02 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AGIO'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56 Med: 0.98 Max: 2.35 Current: 1.02 |
| Earnings Yield (Greenblatt) % | -13.71 |
AGIO's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 1081 Companies in the Global Biotechnology industry. ( Industry Median: -7.73 vs. AGIO: -13.71 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AGIO'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.4 Med: -8.95 Max: -1.1 Current: -13.71 |
| Revenue (TTM) (Mil) $ | 74.17 |
|---|---|
| EPS (TTM) $ | -6.26 |
| Beta | 2.74 |
| Volatility | 57.04% |
| 52-Week Range $ | 41.63 - 99.82 |
| Shares Outstanding (Mil) | 58.18 |
| Dec18 | Dec19 | Dec20 | Dec21 | |
|---|---|---|---|---|
| Revenue (Mil $) | 87 | 209 | 390 | 583 |
| EBIT (Mil $) | -365 | -18 | 45 | 99 |
| EBITDA (Mil $) | ||||
| EPS ($) | -6.02 | -2.80 | -1.55 | 0.37 |
| EPS without NRI ($) | -6.02 | -2.80 | -1.55 | 0.37 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | |||
| Dividends per Share ($) | ||||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP